Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions

NEXT STORY
IBA and the University of Pennsylvania partner to advance research of ConformalFLASH® therapy
PREV STORY
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

West Yavapai Guidance Clinic Hosts Open House to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

author_avatar
NASDAQ Market News

Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results

- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash ...

author_avatar
NASDAQ Market News

GBS Inc. Announces its Pre-Submission package is with the FDA

author_avatar
NASDAQ Market News